Literature DB >> 3002327

Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP.

M Bushfield, A McNicol, D E MacIntyre.   

Abstract

It has been proposed that cyclic AMP inhibits platelet reactivity: by preventing agonist-induced phosphoinositide hydrolysis and the resultant formation of 1,2-diacylglycerol and elevation of cytosolic free Ca2+ concentration [( Ca2+]i); by promoting Ca2+ sequestration and/or extrusion; and by suppressing reactions stimulated by (1,2-diacylglycerol-dependent) protein kinase C and/or Ca2+-calmodulin-dependent protein kinase. We used the adenylate cyclase stimulant prostaglandin D2 to compare the sensitivity to cyclic AMP of the transduction processes (phosphoinositide hydrolysis and elevation of [Ca2+]i) and functional responses (shape change, aggregation and ATP secretion) that are initiated after agonist-receptor combination on human platelets. Prostaglandin D2 elicited a concentration-dependent elevation of platelet cyclic AMP content and inhibited platelet-activating-factor(PAF)-induced ATP secretion [I50 (concn. causing 50% inhibition) approximately 2 nM], aggregation (I50 approximately 3 nM), shape change (I50 approximately 30 nM), elevation of [Ca2+]i (I50 approximately 30 nM) and phosphoinositide hydrolysis (I50 approximately 10 nM). A 2-fold increase in cyclic AMP content resulted in abolition of PAF-induced aggregation and ATP secretion, whereas maximal inhibition of shape change, phosphoinositide hydrolysis and elevation of [Ca2+]i required a greater than 10-fold elevation of the cyclic AMP content. This differential sensitivity of the various responses to inhibition by cyclic AMP suggests that the mechanisms underlying PAF-induced aggregation and ATP secretion differ from those underlying shape change. Thus a major component of the cyclic AMP-dependent inhibition of PAF-induced platelet aggregation and ATP secretion is mediated by suppression of certain components of the activation process that occur distal to the formation of DAG or elevation of [Ca2+]i.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002327      PMCID: PMC1152868          DOI: 10.1042/bj2320267

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Subcellular distribution of the different platelet proteins phosphorylated on exposure of intact platelets to ionophore A23187 or to prostaglandin E1. Possible role of a membrane phosphopolypeptide in the regulation of calcium-ion transport.

Authors:  J E Fox; A K Say; R J Haslam
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

2.  Specific binding sites for prostaglandin D2 on human platelets.

Authors:  A M Siegl; J B Smith; M J Silver
Journal:  Biochem Biophys Res Commun       Date:  1979-09-12       Impact factor: 3.575

Review 3.  Radioimmunoassay of cyclic AMP and cyclic GMP.

Authors:  G Brooker; J F Harper; W L Terasaki; R D Moylan
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

4.  Formation of prostagland in D2 during endoperoxide-induced platelet aggregation.

Authors:  J B Smith; C M Ingerman; M J Silver
Journal:  Thromb Res       Date:  1976-10       Impact factor: 3.944

Review 5.  Hormonal control of protein phosphorylation.

Authors:  H G Nimmo; P Cohen
Journal:  Adv Cyclic Nucleotide Res       Date:  1977

6.  Separation and analysis of 32P-labeled phospholipids by a simple and rapid thin-layer chromatographic procedure and its application to cultured neuroblastoma cells.

Authors:  E Yavin; A Zutra
Journal:  Anal Biochem       Date:  1977-06       Impact factor: 3.365

7.  Compartmentalization of adenosine 3':5'-monophosphate-binding proteins in human platelets.

Authors:  R M Lyons
Journal:  Thromb Res       Date:  1980-08-01       Impact factor: 3.944

8.  Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase.

Authors:  D R Hathaway; C R Eaton; R S Adelstein
Journal:  Nature       Date:  1981-05-21       Impact factor: 49.962

Review 9.  Regulatory mechanisms in the control of protein kinases.

Authors:  D A Flockhart; J D Corbin
Journal:  CRC Crit Rev Biochem       Date:  1982-02

10.  Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.

Authors:  V M Steen; H Holmsen
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

View more
  17 in total

1.  Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.

Authors:  Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

3.  Release of Ca2+ by inositol 1,4,5-trisphosphate in platelet membrane vesicles is not dependent on cyclic AMP-dependent protein kinase.

Authors:  F O'Rourke; G B Zavoico; M B Feinstein
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

4.  Proceedings of the British Pharmacological Society. 10th-18th September 1986. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

5.  Proceedings of the British Pharmacological Society. Bath, 9th-11th April 1986. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

6.  Agents that elevate the concentration of cAMP in platelets inhibit the formation of a NaDodSO4-resistant complex between thrombin and a 40-kDa protein.

Authors:  K M Lerea; J A Glomset
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 7.  The expansive role of oxylipins on platelet biology.

Authors:  Jennifer Yeung; Megan Hawley; Michael Holinstat
Journal:  J Mol Med (Berl)       Date:  2017-05-20       Impact factor: 4.599

8.  Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis.

Authors:  Satori Tokudome; Motoaki Sano; Ken Shinmura; Tomohiro Matsuhashi; Shintaro Morizane; Hidenori Moriyama; Kayoko Tamaki; Kentaro Hayashida; Hiroki Nakanishi; Noritada Yoshikawa; Noriaki Shimizu; Jin Endo; Takaharu Katayama; Mitsushige Murata; Shinsuke Yuasa; Ruri Kaneda; Kengo Tomita; Naomi Eguchi; Yoshihiro Urade; Koichiro Asano; Yasunori Utsunomiya; Takeshi Suzuki; Ryo Taguchi; Hirotoshi Tanaka; Keiichi Fukuda
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

9.  Inactivation of platelet-activating factor by a putative acetylhydrolase from the gastrointestinal nematode parasite Nippostrongylus brasiliensis.

Authors:  C C Blackburn; M E Selkirk
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

10.  Cyclic AMP does not inhibit collagen-induced platelet signal transduction.

Authors:  J B Smith; C Dangelmaier; M A Selak; B Ashby; J Daniel
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.